上海莱士SR604注射液新增适应症获得药物临床试验批准

Core Viewpoint - Shanghai Laishi has received approval from the National Medical Products Administration for clinical trials of SR604 injection for the prevention of bleeding episodes in patients with von Willebrand disease (VWD) [1] Company Summary - The approved clinical trial for SR604 focuses on the indication of "prevention of bleeding episodes in patients with von Willebrand disease" [1] - VWD is a hereditary bleeding disorder caused by abnormalities in von Willebrand factor (VWF) [1] - The company plans to conduct a Phase II dose-exploration trial based on previous hemophilia clinical trials, testing two dosage groups: 0.2 mg/kg administered every 4 weeks and 0.4 mg/kg administered every 4, 6, or 8 weeks [1] - Successful development of this product is expected to significantly improve the medication experience for patients with von Willebrand disease [1]